These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25571289)

  • 1. A pharmacokinetic model of lopinavir in combination with ritonavir in human.
    Duangchaemkarn K; Reisfeld B; Lohitnavy M
    Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5699-702. PubMed ID: 25571289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV.
    Niu WJ; Sun T; Liu L; Liu XQ; Zhang RF; Yin L; Wang JR; Jia XF; Lu HZ; Zhong MK; Jiao Z; Zhang LJ
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):456-465. PubMed ID: 30346663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
    Tasias M; Aldeguer JL
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic profiles of lopinavir (LPV) in Chinese HIV-infected patients].
    Zhang X; Liu Z; Du X; Fu Q; Li T
    Zhonghua Nei Ke Za Zhi; 2015 May; 54(5):431-3. PubMed ID: 26080823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
    Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM;
    Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
    Ramautarsing RA; van der Lugt J; Gorowara M; Wongsabut J; Khongpetch C; Phanuphak P; Ananworanich J; Lange JM; Burger DM; Ruxrungtham K; Avihingsanon A
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):55-8. PubMed ID: 22027875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.
    Pinto JA; Capparelli EV; Warshaw M; Zimmer B; Cressey TR; Spector SA; Qin M; Smith B; Siberry GK; Mirochnick M;
    Pediatr Infect Dis J; 2018 Feb; 37(2):e29-e35. PubMed ID: 29088027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults.
    Rattanapunya S; Cressey TR; Rueangweerayut R; Tawon Y; Kongjam P; Na-Bangchang K
    Am J Trop Med Hyg; 2015 Dec; 93(6):1383-90. PubMed ID: 26416104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
    Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
    Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.
    López Aspiroz E; Cabrera Figueroa SE; Porras Hurtado GL; Cruz Guerrero R; Domínguez-Gil Hurlé A; Carracedo A;
    Curr Drug Metab; 2013 Sep; 14(7):729-37. PubMed ID: 24001122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
    Umeh OC; Currier JS; Park JG; Cramer Y; Hermes AE; Fletcher CV
    J Clin Pharmacol; 2011 Dec; 51(12):1665-73. PubMed ID: 21233301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers.
    Calderón MM; Chairez CL; Gordon LA; Alfaro RM; Kovacs JA; Penzak SR
    Pharmacotherapy; 2014 Nov; 34(11):1151-8. PubMed ID: 25142999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
    Alexander CS; Montaner JS; Asselin JJ; Ting L; McNabb K; Harris M; Guillemi S; Harrigan PR
    Ther Drug Monit; 2004 Oct; 26(5):516-23. PubMed ID: 15385834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
    Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.
    Wang K; D'Argenio DZ; Acosta EP; Sheth AN; Delille C; Lennox JL; Kerstner-Wood C; Ofotokun I
    Clin Pharmacokinet; 2014 Apr; 53(4):361-71. PubMed ID: 24311282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.